44 bet
Bright Future: Natchez Early College student joins esteemed honor societyTORONTO , Dec. 3, 2024 /PRNewswire/ - IsoEnergy Ltd. (" IsoEnergy ") (TSX: ISO) (OTCQX: ISENF ) is pleased to announce shareholders of the company (the " Shareholders ") have overwhelmingly approved two resolutions at the Special Meeting of Shareholders (the " Meeting ") held today. These include the ordinary resolution (the " Share Issuance Resolution ") to approve the share issuance in connection with the previously announced arrangement (the " Arrangement ") involving IsoEnergy and Anfield Energy Corp. (" Anfield ") and the special resolution (the " Share Consolidation Resolution ") approving the discretionary consolidation of IsoEnergy shares. The Share Issuance Resolution was required to be approved by a simple majority of the votes cast by Shareholders virtually in person or represented by proxy at the Meeting and the Share Consolidation Resolution was required to be approved by at least two-thirds (66 2/3%) of the votes cast by Shareholders virtually in person or represented by proxy at the Meeting. A total of 116,633,626 Common Shares, representing approximately 65.23% of votes entitled to be cast at the Meeting, were represented in person or by proxy at the Meeting. Approximately 99.56% of the votes eligible to be cast were voted in favour of the Share Issuance Resolution and 99.19% in favour of the Share Consolidation Resolution. The report of voting results will be made available under IsoEnergy's profile on SEDAR+ at www.sedarplus.ca . In addition to the approval by IsoEnergy Shareholders, Anfield shareholders approved the Arrangement at its special meeting today. Anfield will seek a final order approving the Arrangement from the Supreme Court of British Columbia on December 6, 2024 . Closing of the Arrangement remains subject to satisfaction of certain customary closing conditions, including receipt of final court and stock exchange approvals. Subject to the satisfaction of these closing conditions, the parties currently expect to complete the Arrangement in December 2024 . IsoEnergy is also pleased to announce that the parties have received written notice from the Committee on Foreign Investment in the United States that it has concluded its review of the Arrangement and determined that there are no unresolved national security concerns with respect to the Arrangement. Further details regarding the Arrangement, including the principal closing conditions and the anticipated benefits for Shareholders, can be found in the Company's management proxy circular dated October 31, 2024 , in respect of the Meeting, which can be found under the Company's SEDAR+ profile at www.sedarplus.ca . None of the securities to be issued pursuant to the Arrangement have been or will be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and any securities issuable in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Cautionary Statement Regarding Forward-Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". These forward-looking statements or information may relate to the Arrangement, including statements with respect to the consummation of the Arrangement and the timing thereof; satisfaction of conditions to closing of the Arrangement, including receipt of final court and stock exchange approvals; and any other activities, events or developments that the companies expect or anticipate will or may occur in the future. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management at the time, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such assumptions include, but are not limited to, assumptions that IsoEnergy and Anfield will complete the Arrangement in accordance with, and on the timeline contemplated by the terms and conditions of the relevant agreements; that the parties will receive the required court and stock exchange approvals and will satisfy, in a timely manner, the other conditions to the closing of the Arrangement; and that general business and economic conditions will not change in a material adverse manner . Although IsoEnergy has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Such statements represent the current views of IsoEnergy with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by IsoEnergy, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Risks and uncertainties include, but are not limited to the following: the inability of IsoEnergy and Anfield to complete the Arrangement; a material adverse change in the timing of and the terms and conditions upon which the Arrangemen tis completed; the inability to satisfy or waive all conditions to closing the Arrangement; the failure to obtain shareholder, regulatory, court or stock exchange approvals in connection with the Arrangement; unanticipated changes in market price for IsoEnergy Shares and/or Anfield shares; changes to IsoEnergy's and/or Anfield's current and future business plans and the strategic alternatives available thereto; growth prospects and outlook of Anfield's business; regulatory determinations and delays; stock market conditions generally; demand, supply and pricing for uranium; and general economic and political conditions in Canada , the United States and other jurisdictions where the applicable party conducts business. Other factors which could materially affect such forward-looking information are described in the risk factors in IsoEnergy's most recent annual information form, the Circular and IsoEnergy's other filings with the Canadian securities regulators which are available, respectively, on each company's profile on SEDAR+ at www.sedarplus.ca . IsoEnergy does not undertake to update any forward-looking information, except in accordance with applicable securities laws. SOURCE IsoEnergy Ltd.Shocking Nvidia Move! New GPU Launch Could Shake the MarketZomato said last week that it received a notice from the goods and services tax authorities demanding Rs 803 crore in unpaid tax including penalty and interest for the period between 2019 and 2022. This issue pertains to a contention between food delivery platforms and the government, on whether the aggregators are liable to pay tax on the delivery fees collected by them. ET explains: What is the latest development? The tax demand came after the GST authorities sent a show cause notice to Zomato in December last year , seeking reasons on why it should not be taxed the amount. The authorities decided to raise the demand after taking into consideration the company’s response. Why is Zomato being asked to pay such a large amount in tax? Web Development Intermediate Java Mastery: Method, Collections, and Beyond By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Web Development Advanced C++ Mastery: OOPs and Template Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Entrepreneurship Crafting a Powerful Startup Value Proposition By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Web Development 12-Factor App Methodology: Principles and Guidelines By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Java 21 Essentials for Beginners: Build Strong Programming Foundations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Excel Essentials to Expert: Your Complete Guide By - Study At Home, Quality Education Anytime, Anywhere View Program Design Microsoft Designer Guide: The Ultimate AI Design Tool By - Prince Patni, Software Developer (BI, Data Science) View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Entrepreneurship From Idea to Product: A Startup Development Guide By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Finance Crypto & NFT Mastery: From Basics to Advanced By - CA Raj K Agrawal, Chartered Accountant View Program Entrepreneurship Startup Fundraising: Essential Tactics for Securing Capital By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Entrepreneurship Building Your Winning Startup Team: Key Strategies for Success By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) Collaborative AI Foundations: Working Smarter with Machines By - Prince Patni, Software Developer (BI, Data Science) View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Data Analysis Animated Visualizations with Flourish Studio: Beginner to Pro By - Prince Patni, Software Developer (BI, Data Science) View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Web Development Maximizing Developer Productivity: The Pomodoro Technique in Practice By - Prince Patni, Software Developer (BI, Data Science) View Program The tax demand pertains to dues between October 2019 and March 2022. The GST authorities are of the view that delivery is classified as a service and so the fees collected by Zomato during this period is liable to be taxed. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories At the heart of this issue is Section 9 (5) of the Central GST Act, which stipulates that platforms across sectors such as food delivery, ride hailing and ecommerce that aggregate businesses are responsible for collection and payment of the indirect tax on behalf of the suppliers of goods or services. Under GST laws, delivery of food is a service liable to be taxed at 18%, and the government is of the view that since the platforms have been collecting a service fee, they must pay the tax. What is the point of contention? Aggregators say that while they collect delivery fees from customers, it is passed on to the gig workers fulfilling those deliveries. “In a large number of cases, customers are charged no delivery fees or discounted fees...but the delivery partners are still paid as per a standard per km fee basis. That’s the burden the platform takes to drive growth,” a food delivery executive said. How long has this issue been in the making? Starting January 1, 2022 , online food ordering platforms that aggregate restaurants and arrange for food deliveries have been liable to collect and deposit GST on behalf of restaurants for sales made through them. However, at the time, no clarity was provided on the delivery fee component. Companies and industry bodies have been seeking clarity from the GST Council on the delivery fee component, on whether it is covered under the tax ambit. But nothing has emerged so far. How does this tax demand impact Zomato? The company said it will contest the tax demand. It will first appeal in the GST Appellate Tribunal, following which the matter could end up going to the courts. “This will be a long-drawn battle before any material outcome emerges,” a tax expert said. To put things into perspective, the tax demand of Rs 803.7 crore is more than the total profit made by Zomato since it became profitable in the April-June 2023 quarter. In the fiscal year 2024, Zomato posted a net profit of Rs 351 crore . For the first six months of the ongoing fiscal year, it posted a profit of Rs 429 crore. What could be the broader implications? While the final outcome of this matter could take time as the company as well the authorities undergo a likely appeals process, a legal precedence on paying tax for delivery fees collected on behalf of gig workers could open the gates for other services that employ gig workers for deliveries, such as online groceries, e-pharmacies, and hyperlocal logistics to be taxed. Is it just Zomato that has come under the tax scanner on this issue? Zomato’s Bengaluru-based rival Swiggy was also served a show cause notice last December on the same matter amounting to unpaid tax of Rs 326.8 crore. Swiggy is understood to have not received a demand notice yet.
Tesla Model Q Specs Leaked, Will Start At Under $30,000?
Decorating your front yard with string lights is the perfect way to bring some festivity to your home. But it can be a little tricky to work out how many lights you need. You have to weave the lights in and out of branches, so simply measuring the length of a hedge isn't enough. It's easy to underdo it and run out of lights, or buy too many and wind up with a blazing bright front yard. I spoke to a lighting expert and electrician who gave me a handy rule of thumb for working out how many LED bulbs you need to decorate your front yard at Christmas. In short, you need fifty LEDs per square foot, but there are some little things to bear in mind before you set up your outdoor Christmas lights . The fifty per foot rule Electrician and lighting expert Joel Worthington gave me a rough rule for working out how many Christmas lights you need: 'Generally, you about 50 to 100 lights per square foot for a dense and vibrant look.' So, if you know you need to cover ten feet of shrubs with Christmas lights, you need 500 bulbs to create good coverage. That sounds like a lot, but you need to cover the whole surface of the bush, so you need lots of tiny LED bulbs. Joel is an elecrical expert and oversees operations of 170 North American franchise locations and international master franchisees. Established in 1994, Mr. Electric is a global franchise organization providing electrical installation and repair services. Lighting shrubs The fifty-per-foot rule is most applicable to shrubs and bushes. If you have some boxwood or yew bushes to light up, use fifty lights of string light per square foot. However, by far the easiest way to cover these plants is to use net lights. You don't need to do any math or wind the lights through branches and leaves. Net lights use a big lattice of wire and LEDs, so you can throw the whole set over the top of a bush or shrub. All you need to do is measure the plant - or even just the visible surface area if it backs onto a wall or fence - and then buy the right size online. Net lights are easy to find - you can get a set of net lights like this on Amazon for less than $20. Lighting trees Joel's fifty per foot rule applies to trees too. The usual rule for lighting Christmas trees indoors is to use 100 lights per foot of tree, but this might be a little too much light for outdoor decor. It can also add up to a lot of lights - if you have a 20-foot tree to light, 2000 lights might be overkill. So, for lighting a tree in the front yard, use around fifty bulbs per foot. This will create a cozy, welcoming effect that's less intense than Alternatively, you could uplight the tree. This is always an easier way to light a tree than hanging up lengths of Christmas string lights. All you need to do is place a small stake light at the base of the tree and aim it up at the branches. This can create festive lighting much faster than using lots of lights. Lighting walls and fences You can adapt this rule for lighting walls and fences with string lights. You don't need fifty bulbs per square foot but aim for around fifty bulbs by the length of the surface. A 10-foot stretch of wall needs around 500 lights, but they don't need to cover the entire wall. That's because string lights on fences and walls don't need to illuminate the entire structure. It would look harsh and garish to put too much focus on a wood fence or brick wall. A single train of lights draped along a wall will do the trick, so don't feel as though you need to overdo it. Don't get caught up on the rule However, bear in mind that this is a rule of thumb to help you work out how many LEDs you need. You can increase or decrease the amount of lights depending on the effect you want to achieve. For a brighter yard, bump the numbers up to 100 lights per square foot; for a more relaxed look, decrease it to 25 diodes per foot. Lighting expert Dara Greaney says 'There is ultimately no correct number for the amount of lights you need per square foot. Our recommendation is always to keep things as consistent as possible, so the same strand that you ran across the house should be used on shrubs and bushes. That way you have a consistent lights per square foot, as opposed to trying to hit a specific target.' Dara Greaney is the CEO and President of LEDLightExpert.com, a leading company in commercial lighting solutions. During that time LED Light Expert has sold hundreds of millions of dollars worth of LED Lights. Greaney has extensive expertise in lighting design, LED technology, and fixture design. With the number of LED bulbs sorted, you have a crucial decision to make about your Christmas color scheme. Weighing up the best outdoor Christmas light colors can help you work out the perfect festive lighting for your home.Cowboys’ Stephen Jones expects ‘really tight’ offseason in 2025
Akira Hiyoshi, his wife and 6-year-old son were returning from the customary first shrine visit of the new year and about to enter their house when the earth began to convulse. Roof tiles on their century-old sake brewery — adjacent to their home in the city of Wajima, Ishikawa Prefecture — came raining down, and the structure began collapsing before their eyes. “My wife said she heard me muttering ‘It’s over,’ while we stared at what was unfolding,” says the fifth-generation owner and tōji , or master brewer, of Hiyoshi Sake Brewery, which is known for its Kinpyo Shirakoma brand of sake.SAN DIEGO, Dec. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zeta Global Holdings Corp. (NYSE: ZETA) securities between February 27, 2024 and November 13, 2024, inclusive (the “Class Period”), have until January 21, 2025 to seek appointment as lead plaintiff of the Zeta Global class action lawsuit. Captioned Davoodi v. Zeta Global Holdings Corp. , No. 24-cv-08961 (S.D.N.Y.), the Zeta Global class action lawsuit charges Zeta Global as well as certain of Zeta Global’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Zeta Global class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-zeta-global-holdings-corp-class-action-lawsuit-zeta.html You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com . CASE ALLEGATIONS : Zeta Global is a marketing technology company. The Zeta Global class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Zeta Global used two-way contracts to artificially inflate financial results; (ii) Zeta Global engaged in round trip transactions to artificially inflate financial results; (iii) Zeta Global utilized predatory consent farms to collect user data; and (iv) these consent farms have driven almost the entirety of Zeta Global’s growth. The Zeta Global class action lawsuit further alleges that on November 13, 2024 Culper Research published a report entitled “Zeta Global Holdings Corp (ZETA): Shams, Scams, and Spam.” On this news, the price of Zeta Global’s stock fell by more than 37%. THE LEAD PLAINTIFF PROCESS : The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Zeta Global securities during the Class Period to seek appointment as lead plaintiff in the Zeta Global class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Zeta Global class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Zeta Global class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Zeta Global class action lawsuit. ABOUT ROBBINS GELLER : Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities-fraud.html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@rgrdlaw.com
Penguins goaltender Alex Nedeljkovic scheduled to start against Utah Hockey ClubThe standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.
The rumor mill is churning with exciting news for Apple enthusiasts! Leaks suggest that Apple is poised to launch its slimmest iPhone yet, tentatively named the iPhone 17 Air. This new model is expected to redefine smartphone design with its incredibly thin profile, potentially measuring between 5mm and 6mm. To put that into perspective, the current iPhone 16 Pro measures 8.25mm thick, and the thinnest iPhone to date, the 2014 iPhone 6, was 6.9mm thick. This development marks a significant shift in Apple’s design philosophy, pushing the boundaries of engineering and aesthetics. The “Air” moniker, synonymous with lightweight and sleek design in Apple’s product line (think MacBook Air and iPad Air), hints at the company’s ambition to achieve a new level of portability and elegance in its smartphones. But this ambitious design reportedly comes with some trade-offs, including potential compromises on battery life, camera capabilities, and connectivity. A New Era of Slim If the leaks are accurate, the iPhone 17 Air will be drastically thinner than any previous iPhone model. This radical reduction in thickness is generating considerable buzz among tech enthusiasts and raising questions about how Apple plans to achieve this feat without sacrificing functionality. Here’s what we’ve gathered from various sources: Design Challenges and Potential Trade-offs Creating an ultra-thin smartphone like the rumored iPhone 17 Air presents significant engineering challenges. Fitting all the necessary components – battery, processor, camera modules, and more – into such a slim profile requires innovative design and space optimization. Here are some potential challenges and trade-offs Apple might face: What About the Features? While the focus is on the iPhone 17 Air’s thin design, we can anticipate that Apple will still pack it with powerful features. Expected features include: My Thoughts Personally, I’m intrigued by the idea of an ultra-thin iPhone . I’ve always valued sleek and lightweight devices, and the iPhone 17 Air seems to take this to the extreme. However, I’m also cautious about the potential compromises. Battery life is crucial for me, and I wouldn’t want to sacrifice it for a thinner phone. I’m also curious to see how Apple addresses the challenges related to camera technology and speaker quality. I remember when the iPhone 6 came out, and how its thin design was a major selling point. But it also faced criticism for its susceptibility to bending. I hope Apple has learned from that experience and will ensure the iPhone 17 Air is durable enough for everyday use. The iPhone 17 Air is still shrouded in speculation, and we’ll have to wait for official announcements from Apple to confirm the final design and features. However, the leaks have certainly sparked excitement and anticipation among iPhone users. If Apple can successfully navigate the design challenges and deliver a truly compelling ultra-thin iPhone without significant compromises, the iPhone 17 Air could be a game-changer in the smartphone market. What do you think about the prospect of an ultra-thin iPhone? Are you excited about the potential design or concerned about the possible trade-offs? Share your thoughts in the comments below!
Syrian insurgents reach the capital's suburbs. Worried residents flee and stock up on supplies BEIRUT (AP) — Insurgents’ stunning march across Syria is gaining speed with news that they have reached the suburbs of the capital of Damascus. The government on Saturday was forced to deny rumors that President Bashar Assad had fled the country. The rebels’ moves around Damascus were reported by an opposition war monitor and a rebel commander. They came after the Syrian army withdrew from much of southern part of the country, leaving more areas, including two provincial capitals, under the control of opposition fighters. The advances in the past week were among the largest in recent years by opposition factions. The factions are by a group that has its origins in al-Qaida and is considered a terrorist organization by the U.S. and the United Nations. An archbishop's knock formally restores Notre Dame to life as winds howl and heads of state look on PARIS (AP) — France’s iconic Notre Dame Cathedral has formally reopened its doors for the first time since a devastating fire nearly destroyed the 861-year-old landmark in 2019. The five-year restoration is widely seen as a boost for French President Emmanuel Macron, who championed the ambitious timeline, and brings a welcome respite from his domestic political woes. World leaders, dignitaries, and worshippers gathered on Saturday evening for the celebrations under the cathedral's soaring arches. The celebration was attended by 1,500 dignitaries, including President-elect Donald Trump, Britain’s Prince William, and Ukrainian President Volodymyr Zelenskyy. For Catholics, Notre Dame’s rector said the cathedral “carries the enveloping presence of the Virgin Mary, a maternal and embracing presence.′′ Trump is welcomed by Macron to Paris with presidential pomp and joined by Zelenskyy for their talks PARIS (AP) — French President Emmanuel Macron has welcomed Donald Trump to Paris with a full dose of presidential pomp. And they held a hastically-arranged meeting with Ukraine’s Volodymyr Zelenskyy on a day that's mixing pageantry with attention to pressing global problems. The president-elect's visit to France is part of a global a celebration of the reopening of Notre Dame Cathedral five years after a devastating fire. Macron and other European leaders are trying to win Trump’s favor and persuade him to maintain support for Ukraine in its defense against Russia’s invasion. Trump isn't back in office but he's already pushing his agenda and negotiating with world leaders NEW YORK (AP) — Donald Trump is making threats, traveling abroad, and negotiating with world leaders. He has more than a month-and-a-half to go before he’s sworn in for a second term. But the president-elect is already moving aggressively to not only fill his Cabinet and outline policy goals, but also to try to achieve his priorities. In recent days, Trump has threatened to impose a 25% tariff on goods from Canada and Mexico, two of the country’s largest trading partners. That led to emergency calls and a visit. And he's warned of “ALL HELL TO PAY” if Hamas doesn't release the hostages still being held captive in Gaza. South Korea's president avoids an impeachment attempt over short-lived martial law SEOUL, South Korea (AP) — South Korea’s embattled President Yoon Suk Yeol has avoided an opposition-led attempt to impeach him over his short-lived imposition of martial law. Most of Yoon's ruling party lawmakers boycotted a parliamentary vote Saturday to deny a two-thirds majority needed to suspend his presidential powers. The scrapping of the motion is expected to intensify protests calling for Yoon’s ouster and deepen political chaos in South Korea. A survey suggests a majority of South Koreans support the president’s impeachment. Yoon’s martial law declaration drew criticism from his own ruling conservative People Power Party. But the party also apparently fears losing the presidency to liberals. Days after gunman killed UnitedHealthcare's CEO, police push to ID him and FBI offers reward NEW YORK (AP) — Nearly four days after the shooting of UnitedHealthcare CEO Brian Thompson, police still do not know the gunman’s name or whereabouts or have a motive for the killing. But they have made some progress in their investigation into Wednesday's killing of the leader of the largest U.S. health insurer, including that the gunman likely left New York City on a bus soon after fleeing the scene. The also found that the gunman left something behind: a backpack that was discovered in Central Park. Police are working with the FBI, which on Friday night announced a $50,000 reward for information leading to an arrest and conviction. UnitedHealthcare CEO's shooting opens a door for many to vent frustrations over insurance The fatal shooting of UnitedHealthcare's CEO has opened the door for many people to vent their frustrations and anger over the insurance industry. The feelings of exasperation, anger, resentment, and helplessness toward insurers aren’t new. But the shooting and the headlines around it have unleashed a new wave of patients sharing such sentiments and personal stories of interactions with insurance companies. Conversations at dinner tables, office water coolers, social gatherings and on social media have pivoted to the topic. Many say they hope the new amplified voices can bring about change for companies often accused of valuing profits over people. 2 Pearl Harbor survivors, ages 104 and 102, return to Hawaii to honor those killed in 1941 attack PEARL HARBOR, Hawaii (AP) — The bombing of Pearl Harbor 83 years ago launched the United States into World War II. Two survivors returned to the Hawaii military base on Saturday for a remembrance ceremony on the attack's anniversary. Both are over 100 years old. They joined active-duty troops, veterans and members of the public for an observance hosted by the Navy and the National Park Service. A third survivor was planning to join them but had to cancel due to health issues. The bombing killed more than 2,300 U.S. servicemen. An explosion destroys an apartment block in a Dutch city, killing at least 3 and injuring others THE HAGUE, Netherlands (AP) — An explosion and fire has rocked a neighborhood in the Dutch city of The Hague, killing three people and injuring other people and destroying several apartments. The cause of the disaster is unclear. Emergency authorities said four people were rescued from the rubble and taken to the hospital. The mayor said rescuers were no longer looking for survivors but for eventual bodies, but could not specify how many people might still be unaccounted for. Residents of the northeastern neighborhood of Mariahoeve in The Hague heard a huge bang and screams before dawn. Dutch authorities have deployed a specialized urban search and rescue team to find victims. How 'Mufasa' rose with Aaron Pierre and Blue Ivy's voices along with new Lin-Manuel Miranda music SAN DIEGO (AP) — When Aaron Pierre was cast as Mufasa, the weight of following in the late James Earl Jones’ legendary footsteps was enough to rattle any actor. But instead of letting the pressure roar too loudly, he harnessed his nerves to breathe fresh life into his young lion character. Pierre found parallels between himself and his character while filming his leading role in “Mufasa: The Lion King,” which opens in theaters Dec. 20. He took the reigns as the new voice of Mufasa after Jones played the iconic King Mufasa in both the 1994 and 2019 versions of Disney’s “The Lion King.” The prequel offers a fresh exploration into Mufasa’s origin story.FLORENCE, Italy & BARCELONA, Spain--(BUSINESS WIRE)--Dec 11, 2024-- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with MEDSIR, a leading global independent clinical research company in oncology and part of Oncoclínicas & Co., the largest specialized oncology treatment group in Latin America, presented research on the pioneering clinical trial ADELA. This important research addresses therapeutic resistance in advanced ER+/HER2- breast cancer. Presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), the study represents a key milestone in the quest for more effective and personalized treatment options for patients with disease progression. The standard first-line treatment for advanced ER+/HER2- breast cancer combines endocrine therapy with CDK4/6 inhibitors. ESR1 mutations develop as a result of prior exposure to endocrine therapy during metastatic treatment, and up to 50% of ER+, HER2- advanced or metastatic breast cancers will develop these mutations. ESR1 mutations cause the tumors to become resistant to endocrine therapy, in turn causing the cancer to progress; therefore, it is important to test for ESR1 whenever mBC progresses. Longer exposure to endocrine therapy during first-line treatment increases the chance of a patient’s tumor developing an ESR1 mutation. With the goal of addressing this unmet medical need, the ADELA phase III clinical trial investigates a new therapeutic option combining elacestrant, a next generation, oral selective estrogen receptor degrader, with everolimus, an mTORC1 inhibitor. This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors ESR1 mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant’s approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in the phase 1b/2 ELEVATE study ( NCT05563220 ). “We at Menarini Stemline are delighted to announce the collaboration with MEDSIR to continue advancing the clinical research to explore the combination therapy with elacestrant,” said Nassir Habboubi, MD, Chief Medical Officer of Stemline Therapeutics. “We are committed to driving innovation in cancer treatment by delivering transformational therapies aiming to extend the lives of people living with cancer.” The primary objective of this international, randomized, double-blind trial is to evaluate whether the combination of elacestrant and everolimus offers greater efficacy in delaying disease progression compared to elacestrant monotherapy. Additionally, it investigates other crucial aspects, such as overall survival, toxicity profile, and the impact on patients’ quality of life. The ADELA study represents a critical step in understanding how to overcome tumor resistance challenges in patients with ESR1 mutations, with the goal of advancing towards more effective and safer treatments. “At MEDSIR, we understand innovation not only as achieving clinical results but as the ability to transform patients' lives on a global scale. With ADELA, we take a decisive step toward accomplishing less invasive and more accessible treatments, aiming to offer new hope to those facing the most complex forms of the disease. This advancement reinforces our commitment to increasingly personalized and patient-centered medicine, a fundamental pillar in shaping the future of oncology,” said Dr. Antonio Llombart-Cussac, Senior Scientific Leader at MEDSIR. The phase III study not only has significant clinical objectives, but also holds the potential to pave the way for regulatory approval of this therapeutic combination, enabling its use in a broader population of patients with advanced breast cancer. Moreover, the international scope of the study, which includes participation from multiple countries, including Spain, Italy, France, Austria, the Czech Republic, Greece, Germany, and the United Kingdom, underscores the study’s global importance and relevance in the scientific community. The presentation of the ADELA study at an event as prominent as SABCS 2024 reinforces MEDSIR’s leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in breast cancer treatment. The ADELA study is active and already recruiting patients. About ORSERDU (elacestrant) U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Full prescribing information for the U.S. can be found at www.orserdu.com . Important Safety Information Warning and Precautions Dyslipidemia : Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU. Embryo-Fetal Toxicity : Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose. Adverse Reactions Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). The most common adverse reactions (≥10%) , including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%). Drug interactions Concomitant use with CYP3A4 Inducers and/or inhibitors : Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU. Use in specific populations Lactation : Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose. Hepatic Impairment : Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B). The safety and effectiveness of ORSERDU in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . About The Menarini Group The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com . About Stemline Therapeutics Inc. Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU ® (elacestrant) in the U.S. and Europe, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS ® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date. Stemline also commercializes NEXPOVIO ® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers. About MEDSIR Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials. With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: www.medsir.org About Oncoclínicas & CO Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a specialized and innovative model focused on the entire oncology care journey, combining operational efficiency, humanized care, and high specialization through a medical team composed of over 2,700 specialist physicians with an emphasis on oncology. With its mission to democratize cancer treatment, it offers a comprehensive system that integrates outpatient clinics with high-complexity cancer centers. The company operates 145 units across 39 Brazilian cities, allowing high-quality access in all regions it serves, aligned with world-class standards. Focusing on technology, precision medicine, and genomics, Oncoclínicas performed approximately 635,000 treatments in 2023. It is the exclusive partner in Brazil of the Dana Farber Cancer Institute, affiliated with Harvard Medical School, one of the world’s leading cancer research and treatments centers. The company also owns Boston Lighthouse Innovation, a bioinformatics firm based in Cambridge, United States, and holds shares in Medsir, a company dedicated to the development and management of clinical trials for independent cancer research, based in Barcelona, Spain. Recently, Oncoclínicas expanded its operations to Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its mission to beat cancer to a new continent and providing advanced oncology care on a global scale by combining oncological hyperspecialization with innovative treatment approaches. The company is part of the IDIVERSA index, launched by B3, highlighting companies committed to gender and racial diversity. For more information, visit: www.grupooncoclinicas.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241211008868/en/ CONTACT: Media Contacts The Menarini Group Valeria Speroni Cardi Email:pressoffice@menarini.comStemline Therapeutics, Inc. Cheya Pope Email:media@menarinistemline.comGlobal Brand Communication MEDSIR: Sergio Aguilar Global Brand & Communication Director +34 674 82 87 24 sergio.aguilar@medsir.orgEduardo Martín Espallargas Global Communication & Marketing Manager +34 634 835 389 Eduardo.martin@medsir.orgCarles Berloso Cortés International PR & Comms +34 677 49 75 23 carles.berloso@medsir.org KEYWORD: TEXAS SPAIN NORTH AMERICA UNITED STATES EUROPE ITALY INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: The Menarini Group Copyright Business Wire 2024. PUB: 12/11/2024 06:35 PM/DISC: 12/11/2024 06:35 PM http://www.businesswire.com/news/home/20241211008868/en
Joly touts ‘private’ diplomacy as Mexico criticizes Canada’s culture, tradeEven with access to blockbuster obesity drugs, some people don't lose weightA new study reveals Dundee as the cleanest city in the UK
"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.
AP Trending SummaryBrief at 6:46 p.m. ESTAfter weeks of fear and bewilderment about the drones buzzing over parts of New York and New Jersey , U.S. Senator Chuck Schumer is urging the federal government to deploy better drone-tracking technology to identify and ultimately stop the airborne pests. The New York Democrat is calling on the Department of Homeland Security to immediately deploy special technology that identifies and tracks drones back to their landing spots, according to briefings from his office. Schumer’s calls come amid growing public concern that the federal government hasn’t offered clear explanations as to who is operating the drones, and has not stopped them. National security officials have said the drones don’t appear to be a sign of foreign interference. “There’s a lot of us who are pretty frustrated right now,” said Rep. Jim Himes, D-Conn., the top Democrat on the House Intelligence Committee, on Fox News Sunday. “The answer ‘We don’t know’ is not a good enough answer.” President-elect Donald Trump posted on social media last week: “Can this really be happening without our government’s knowledge? I don’t think so. Let the public know, and now. Otherwise, shoot them down.” Certain agencies within the Department of Homeland Security have the power to “incapacitate” drones, U.S. Secretary of Homeland Security Alejandro Mayorkas told ABC’s George Stephanopoulos on Sunday. “But we need those authorities expanded,” he said, without saying exactly how. The drones don’t appear to be linked to foreign governments, Mayorkas said. “We know of no foreign involvement with respect to the sightings in the Northeast. And we are vigilant in investigating this matter,” Mayorkas said. Last year, federal aviation rules began requiring certain drones to broadcast their identities. It’s not clear whether that information has been used to determine who is operating the drones swarming locations in New York and New Jersey. Mayorkas’ office didn’t immediately respond to questions about whether they’ve been able to identify drones using this capability. Schumer is calling for recently declassified radar technology to be used to help determine whether an object is a drone or a bird, identify its electronic registration, and follow it back to its landing place. New York Gov. Kathy Hochul on Sunday said federal officials were sending a drone detection system to the state. “This system will support state and federal law enforcement in their investigations,” Hochul said in a statement. The governor did not immediately provide additional details, including where the system will be deployed. Dozens of mysterious nighttime flights started last month over New Jersey, raising concerns among residents and officials. Part of the worry stems from the flying objects initially being spotted near the Picatinny Arsenal, a U.S. military research and manufacturing facility and over Trump’s golf course in Bedminster. Drones are legal in New Jersey for recreational and commercial use, but they are subject to local and Federal Aviation Administration regulations and flight restrictions. Operators must be FAA certified.AP Business SummaryBrief at 6:15 p.m. EST